title: Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells.
abstract: Bone marrow endothelial cells (EC) from patients with multiple myeloma (MM) were found to express and secrete higher amounts of the CXC-chemokines CXCL8/interleukin (IL)-8, CXCL11/interferon-inducible T-cell alpha chemoattractant (I-TAC), CXCL12/stromal cell-derived factor (SDF)-1alpha, and CCL2/monocyte chemotactic protein(MCP)-1 than EC from human umbilical vein (HUVEC), considered as a healthy counterpart. Paired plasma cells and several MM cell lines expressed cognate receptors of each chemokine to a variable extent. When cells were exposed to chemokines, CXCL8/IL-8 and CXCL12/SDF-1alpha stimulated their proliferation and all chemokines stimulated cell chemotaxis. It is suggested that angiogenesis also favours MM progression through the release of CXC-chemokines.
authors.affiliation: Section of Medical Oncology, Hospital Vito Fazzi, Lecce.
authors.forename: Antonio
authors.initials: A
authors.lastname: Pellegrino
authors.forename: Roberto
authors.initials: R
authors.lastname: Ria
authors.forename: Giulia
authors.initials: G
authors.lastname: Di Pietro
authors.forename: Teresa
authors.initials: T
authors.lastname: Cirulli
authors.forename: Giammarco
authors.initials: G
authors.lastname: Surico
authors.forename: Angela
authors.initials: A
authors.lastname: Pennisi
authors.forename: Fortunato
authors.initials: F
authors.lastname: Morabito
authors.forename: Domenico
authors.initials: D
authors.lastname: Ribatti
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western / Q000379:methods; D001854:Bone Marrow Cells / Q000276:immunology* / Q000378:metabolism; D016022:Case-Control Studies; D002450:Cell Communication; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D054371:Chemokine CXCL11; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D042783:Endothelial Cells / Q000276:immunology* / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016209:Interleukin-8 / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology* / Q000503:physiopathology; D010950:Plasma Cells / Q000276:immunology*; D019707:Receptors, Chemokine / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013268:Stimulation, Chemical
chemical_list: C111835:CCL2 protein, human; C515202:CXCL11 protein, human; C515255:CXCL12 protein, human; D018932:Chemokine CCL2; D054371:Chemokine CXCL11; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D016209:Interleukin-8; D019707:Receptors, Chemokine